• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Analysis on signal transduction pathway through CD103 molecule

Research Project

Project/Area Number 20591193
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 膠原病・アレルギー・感染症内科学
Research InstitutionSaitama Medical University

Principal Investigator

TAKEUCHI Tsutomu  Saitama Medical University, 医学部, 教授 (50179610)

Co-Investigator(Renkei-kenkyūsha) KAMEDA Hideto  慶應義塾大学, 医学部, 講師 (00265795)
YOSHIMOTO Keiko  慶應義塾大学, 医学部, 研究員 (20383292)
Project Period (FY) 2008 – 2010
Project Status Completed (Fiscal Year 2010)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Keywords自己免疫 / 上皮障害 / カドヘリン / インテグリン / CD103 / シグナル伝達 / CDIO3
Research Abstract

Given the evidence that αEβ7(CD03) expressed on T cells is involved in adhesion with E-cadherin on epithelial cells, the CD103 molecule may play a wide variety role in cellular function. In this study, it has been shown that for induction of CD103, not only the expression of TGF-βreceptor by lectin, but also signal transduction through Smad 2/3 is required. After expression of CD103, T cells become proliferate poor, and exhibit unique cytokine prolife. Since CD103+subset of cells can mediate immune-regulatory and immune- inflammatory function, farther investigation may be regained to dissect thesignal leady to two distinct function.

Report

(4 results)
  • 2010 Annual Research Report   Final Research Report ( PDF )
  • 2009 Annual Research Report
  • 2008 Annual Research Report
  • Research Products

    (23 results)

All 2010 2009 2008

All Journal Article (20 results) (of which Peer Reviewed: 20 results) Presentation (3 results)

  • [Journal Article] Efficacy and safety of cycl osporine A in patients with refractory. systemic lupus erythematosus in a dail y clinical practice.2010

    • Author(s)
      Ogawa H, Kameda H, Amano K, Tak euchi, T.
    • Journal Title

      Lupus

      Pages: 162-169

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Reduced expression of TCR zeta is involved in the abnormal production of cytokines by peripheral T cells of patients with systemic lupus erythematosus.2010

    • Author(s)
      Yoshimoto K, Setoyama Y, Tsuzaka K, Abe T, Takeuchi T.
    • Journal Title

      J Biomed Biotechnol

      Volume: Article ID 509021 Pages: 1-6

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialo-adenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation.2010

    • Author(s)
      Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H, Honda N, Yasaki Y, Itoyama S, Tsuzaka K, Takeuchi T.
    • Journal Title

      Rheumatology

      Volume: 49 Pages: 1789-1791

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Efficacy and safety of cyclosporine A in patients with refractory systemic lupuserythematosus in a daily clinical practice.2010

    • Author(s)
      Ogawa H, Kameda H, Amano K, Takeuchi T.
    • Journal Title

      Lupus

      Volume: 19 Pages: 162-169

    • Related Report
      2010 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice.2010

    • Author(s)
      Ogawa H, Kameda H, Amano K, Takeuchi, T.
    • Journal Title

      Lupus 19

      Pages: 162-169

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] IgG4-positive mufti-organ lymphoproliferative syndrome manife sting as chronic symmetrical sclerosing dacryo-sialo-adenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation.2010

    • Author(s)
      Suzuki K, Tamaru J, Okuyama A, Kameda H, Amano K, Nagasawa H, Nishi, E, Yoshimoto K, Setoyama Y, Kaneko K, Osada H, Honda N, Yasaki Y, Itoyama S, Tsuzaka K, Takeuchi T.
    • Journal Title

      Rheumatology (in press)

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The comparison of efficacy and safety between continuation and discontinuation of methotrexate(MTX)at the commencement of etanercept in patients with active rheumatoid arthritis despite MTX therapy : 24-week results from the JESMR study.2010

    • Author(s)
      Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T, Japan Biological Agent Integrated Consortium(J-BASIC).
    • Journal Title

      Rheumatology (in press)

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] ADAMTS5 is a biomarker for prediction of the response to Infliximab in patients with rheumatoid arthritis.2010

    • Author(s)
      Tsuzaka K, Itami Y, Takeuchi T, Shinozaki N, Morishita T
    • Journal Title

      J Rheumatol (in press)

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Two cases of acut e exacerbation of lupus manifestation a fter re-treatment with rituximab in pha se I/II clinical trial for refractory s ystemic lupus erythematosus.2009

    • Author(s)
      Suzuki K, Kameda H, Kondo K, Tanaka Y, Takeuchi T.
    • Journal Title

      Rheumato logy

      Pages: 198-199

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Sever acute thrombotic exacerbation in two cases with of anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory syystemic lupus erythematosus.2009

    • Author(s)
      Suzuki K, Kameda H, Kondo K, Tanaka Y, Takeuchi T.
    • Journal Title

      Rheumatology 48巻

      Pages: 198-199

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Two cases of acute exacerbation of lupus manifestation after re-treatment with rituximab in phase I/II clinical trial for refractory systemic lupus erythe matosus.2009

    • Author(s)
      Suzuki K, Kameda H, Kondo K, Tanaka Y, Takeuchi T.
    • Journal Title

      Rheumatology 48

      Pages: 198-199

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Prediction of efficacy of anti-TNF biologic agent, infliximab, for rheumatoid arthritis patients using a comprehensive transc riptome analysis of white blood cells.2009

    • Author(s)
      Tanino M, Matoba R, Nakamura S, Kameda H, Amano K, Okayama T, Nagasawa H, Suzuki K, Matsubara K, Takeuchi T.
    • Journal Title

      Biochem Biophys Research Comm 387

      Pages: 261-265

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Single Center Prospective Study for Efficacy and Safety of Tacrolimus in Rheumatoid Arthritis.2009

    • Author(s)
      Suzuki K, Kameda H, Amano K, Nagasawa H, Sekiguchi H, Nishi E, Ogawa H, Tsuzaka K, Takeuchi T.
    • Journal Title

      Rheumatology Int 29

      Pages: 431-146

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Long-term safety and efficacy of tocilizumab, an anti-interleuk in(IL)-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis(the STREAM study) : evidence of safety and efficacy in a 5-year extension study.2009

    • Author(s)
      Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J.
    • Journal Title

      Ann Rheum Dis 68

      Pages: 1580-1584

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Impact to through serum level on Radiographic and Clinical Response to Infliximab plus Methotrexate in Patients with Rheumatoid Arthriti : results from the RISING Study.2009

    • Author(s)
      Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T
    • Journal Title

      Mod Rheumatology 19

      Pages: 478-487

    • Related Report
      2009 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Sever acute thrombotic exacerbation in two cases with of anti-phospholipid syndrome after retreatment with rituximab in phase I/II clinical trial for refractory syystemic lupus erythematosus. .2009

    • Author(s)
      Suzuki K, Kameda H, Kondo K, Tanaka Y, Takeuchi T.
    • Journal Title

      Rheumatology 48

      Pages: 198-199

    • Related Report
      2008 Annual Research Report
    • Peer Reviewed
  • [Journal Article] The conservative sequences in 3'UTR of TCRζ mRNA regulate the production of TCRζ and TCR/CD3 complex in SLE T cells.2008

    • Author(s)
      Tsuzaka K, Itami Y, Kumazawa C, Suzuki M, Setoyama Y, Yoshimoto K, Suzuki K, Abe T, Takeuchi T.
    • Journal Title

      Biochemical Biophysical Research Communications 367巻

      Pages: 311-317

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] Effect of Interleukin 2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells.2008

    • Author(s)
      Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T.
    • Journal Title

      Cytokine 44巻

      Pages: 44-48

    • Related Report
      2010 Final Research Report
    • Peer Reviewed
  • [Journal Article] The conservative sequences in 3'UTR of TCRζ mRNA regulate the production of TCRζ and TCR/CD3 complex in SLE T cells.2008

    • Author(s)
      Tsuzaka K, Itami Y, Kumazawa C, Suzuki M, Setoyama Y, Yoshimoto K, Suzuki K, Abe T, Takeuchi T.
    • Journal Title

      Biochemical Biophysical Research Communications 367

      Pages: 311-317

    • Related Report
      2008 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Effect of Interleukin 2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF)in human peripheral blood mononuclear cells.2008

    • Author(s)
      Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T
    • Journal Title

      Cytokine 44

      Pages: 44-48

    • Related Report
      2008 Annual Research Report
    • Peer Reviewed
  • [Presentation] 免疫難病における新しいターゲット分子と制御2009

    • Author(s)
      竹内勤
    • Organizer
      第37回日本臨床免疫学会総会 シンポジウム3
    • Place of Presentation
      東京
    • Year and Date
      2009-11-14
    • Related Report
      2010 Final Research Report 2009 Annual Research Report
  • [Presentation] The expression of an integrin αEβ7 may induce abnormal T cell activation.2008

    • Author(s)
      K. Yoshimoto, C. Kumazawa, K. Tsuzaka, T. Abe, T. Takeuchi
    • Organizer
      9th annual meeting for European League Aginst Rheumatisam
    • Place of Presentation
      フランス(パリ)
    • Year and Date
      2008-06-14
    • Related Report
      2010 Final Research Report
  • [Presentation] The expression of an integrin α Eβ7 may induce abnormal T cell activation.2008

    • Author(s)
      K. Yoshimoto, C. Kumazawa, K. Tsuzaka, T. Abe, T. Takeuchi.
    • Organizer
      9th annual meeting for European League Aginst Rheumatisam
    • Place of Presentation
      フランス(パジ)
    • Year and Date
      2008-06-14
    • Related Report
      2008 Annual Research Report

URL: 

Published: 2008-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi